Can GLP-1 Drugs Help Fight Periodontal Diseases?

The growing use of GLP-1 receptor agonists presents an unexpected opportunity to examine the connection between systemic metabolic health and periodontal diseases. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), have transformed the management of type 2 diabetes and obesity. As more patients present to dental practices while taking these medications, oral health professionals are uniquely positioned to recognize a key question: Can improvements in systemic health also improve periodontal health? While media attention has largely focused on reports of “Ozempic mouth,” emerging research suggests these medications also offer meaningful periodontal benefits by reducing systemic inflammation, a central contributor to periodontal disease.¹

Individuals with obesity commonly exhibit elevated levels of pro-inflammatory cytokines, including tumor necrosis factor, interleukin-6, and C-reactive protein (CRP), creating a chronic inflammatory environment that may worsen periodontal inflammation and tissue destruction.² Similarly, poorly controlled diabetes alters host immune function, impairs wound healing, and increases susceptibility to periodontal breakdown.^3.4  This bidirectional relationship means that improving systemic metabolic health may also improve periodontal outcomes.^3,4

GLP-1 receptor agonists improve glycemic control while promoting substantial weight loss, but these benefits may extend beyond glucose regulation.⁵ Large clinical trials involving patients with obesity and type 2 diabetes have consistently demonstrated reductions in systemic inflammatory biomarkers, including CRP, as well as improvements in insulin sensitivity and metabolic health. Emerging evidence suggests these medications also reduce oxidative stress and chronic low-grade inflammation, creating a physiologic environment that may favor periodontal healing.⁵ Although these systemic improvements are well established, whether they directly translate into improved periodontal outcomes remains an active area of study.

Researchers have also discovered that GLP-1 receptors are expressed in multiple tissues involved in inflammation, immune regulation, and bone metabolism, suggesting these medications may exert direct biologic effects within the periodontium.¹ Experimental studies demonstrate that GLP-1 receptor activation help reduce inflammation and support the body’s natural ability to preserve bone and repair tissues, both of which are essential for maintaining periodontal health.^1,2 These effects reduce osteoclast activity responsible for alveolar bone resorption while supporting osteoblast function and tissue repair. Animal studies are consistently exhibiting decreased periodontal inflammation, preservation of alveolar bone, and improved periodontal healing following treatment with GLP-1 receptor agonists.^1,2

Although clinical evidence in humans is still emerging, early findings are encouraging. Several observational studies and recent systematic reviews have reported improvements in periodontal parameters among patients receiving GLP-1 receptor agonists, particularly those with type 2 diabetes. Improvements in probing depths, bleeding on probing, and periodontal inflammation have been observed, although the magnitude of benefit varies among studies.⁵ As the number of patients taking GLP-1 receptor agonists continues to grow, further clinical research will be essential to clarify their potential role in periodontal therapy and long-term oral health outcomes.

More recent retrospective cohort studies have strengthened the biologic plausibility of these findings. Investigators comparing patients with type 2 diabetes treated with GLP-1 receptor agonists to those receiving other glucose-lowering medications have reported lower rates of periodontal disease progression, tooth loss, and periodontal treatment needs among GLP-1 users. While observational studies cannot establish causation, they suggest that the anti-inflammatory and metabolic effects of GLP-1 therapy may translate into clinically meaningful oral health benefits and provide additional justification for prospective randomized clinical trials.⁶

Human interventional research is also beginning to emerge. A pilot prospective clinical trial currently registered on clinicaltrials.gov is evaluating periodontal outcomes in patients with periodontitis receiving GLP-1 receptor agonist therapy.⁷ Investigators plan to assess changes in probing depth, bleeding on probing, clinical attachment levels, and inflammatory biomarkers following treatment. Although results have not yet been published, this study represents a meaningful step toward determining whether GLP-1 receptor agonists provide periodontal benefits independent of improvements in weight loss and glycemic control.⁶

These findings reinforce the importance of viewing periodontal diseases through a systemic lens. During comprehensive health history reviews, patients taking GLP-1 medications may report significant weight loss, improved hemoglobin A1c values, lower blood pressure, and healthier dietary habits.⁵ These improvements may positively influence periodontal therapy outcomes, particularly when combined with detailed plaque control, nonsurgical periodontal therapy, and regular periodontal maintenance. As healthcare providers increasingly recognize the bidirectional relationship between periodontal diseases and diabetes, collaboration between dental and medical professionals becomes even more valuable.

At the same time, clinicians should remain aware of potential oral side effects associated with GLP-1 medications. Xerostomia, dehydration, nausea, vomiting, delayed gastric emptying, and gastroesophageal reflux have all been reported and may increase the risk of dental erosion and caries.¹ The severity of erosion depends not only on the acidity of the gastric contents but also on the frequency and duration of acid exposure, making it important to identify patients who experience persistent nausea, vomiting, or reflux. Consequently, comprehensive oral assessments should include evaluation of salivary flow, erosion patterns, dietary changes, hydration status, and oral hygiene practices. Preventive recommendations, including topical fluoride therapy, saliva substitutes when appropriate, dietary counseling, patient education regarding hydration, and guidance to avoid toothbrushing immediately after vomiting or reflux episodes to allow enamel time to remineralize, remain fundamental components of care.

Although the early evidence is promising, important questions remain. Future research will need to determine whether periodontal improvements result primarily from better glycemic control and weight reduction or whether GLP-1 receptor agonists exert independent therapeutic effects within periodontal tissues. Well-designed randomized controlled trials with standardized periodontal outcomes including probing depth reduction, clinical attachment gain, bleeding on probing, inflammatory biomarkers, and radiographic bone changes will be essential before these medications can be considered adjunctive therapies for periodontal diseases. Until then, clinicians should view improved periodontal outcomes as a promising secondary benefit rather than an established indication for GLP-1 therapy. As the evidence base continues to grow, oral health professionals will be well positioned to translate emerging research into clinical practice, ensuring that patient care continues to reflect the evolving relationship between systemic and oral health.

References

1. Barać M, Roganović J. GLP-1 receptor signaling and oral dysfunction: a narrative review on the mechanistic basis of semaglutide-related oral adverse effects. Biology. 2025;14:1650.
2. Pihlstrom BL, Michalowicz BS, Johnson NW. Periodontal diseases. Lancet. 2005;366:1809-1820.
3. Chapple ILC, Genco R; Working group 2 of the Joint EFP/AAP Workshop. Diabetes and periodontal diseases: consensus report of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases. J Clin Periodontol. 2013:40(Suppl 14):106-112.
4. Sanz M, Ceriello A, Buysschaert M, et al. Scientific evidence on the links between periodontal diseases and diabetes: consensus report and guidelines of the Joint Workshop on Periodontitis and Systemic Diseases. J Clin Periodontol. 2018; 45:138-149.
5. Polymeri A, Feres M, Giannobile WV, Loos BG. GLP-1 receptor agonists: bridging diabetes, obesity, and periodontitis — a scoping review of emerging evidence. J Periodontol. 2026;7:1243-1256.
6. Sufaru IG, Vasiliu BC, Hancianu M, et al. GLP-1 receptor agonists in periodontology: mechanisms, clinical evidence, and implications for care. Biomolecules. 2026;16:857.
7. National Library of Medicine. The Influence of GLP1-RA on Periodontal Health: A Pilot Study.